Attending #DPHARM2024? Be sure to check out Steve Rosenberg on stage this morning at 11:35 am where he challenges the industry to expect more from #eCOA #ePRO, and shares why a modern platform must focus on both patient and site experience.
uMotif
Software Development
London, United Kingdom 12,336 followers
Engaged Patients. Better Trials.
About us
uMotif's mission is to put patients at the center of clinical research. Designed with patients for patients, the uMotif patient-first eClinical platform powers site-based to fully decentralized clinical, real-world, and post-marketing research. By engaging patients and healthcare professionals, uMotif is trusted by global pharmaceutical companies, biotechs, CROs, and academic institutions to capture large volumes of eCOA/ePRO, symptom, and wearable device data. www.umotif.com
- Website
-
http://www.uMotif.com
External link for uMotif
- Industry
- Software Development
- Company size
- 51-200 employees
- Headquarters
- London, United Kingdom
- Type
- Privately Held
- Founded
- 2012
- Specialties
- ePRO, digital health, eCOA, clinical trials, patient engagement, real-world studies, late-phase, post-marketing, and non-interventional
Locations
-
Primary
London, United Kingdom, GB
-
Boston, US
Employees at uMotif
Updates
-
Join senior execs including Steve Rosenberg, Bruce Hellman, Florence Mowlem, PhD, Andrea Valente and Don Butler at #pharma and #lifesciences events this fall. Learn how we’re guiding #pharma and #biotech sponsors, sites and patients to demand more from #clinicalresearch technology with modern #eCOA #ePRO and best-in-class #eConsent to improve #clinicaltrials and #realworldstudies. https://lnkd.in/g_j4kDwn DPHARM: Disruptive Innovations to Modernize Clinical Research Society for Clinical Research Sites (SCRS) Society for Clinical Data Management (SCDM) Outsourcing in Clinical Trials Event Series CNS Summit
-
uMotif is gearing up for #DPHARM2024 next week. Stop by booth 38 to find out how we are raising expectations with our modern #eCOA/ #ePRO and best-in-class #eConsent. We look forward to seeing you there! Steve Rosenberg, Kate Shelton, Michael McGloughlin, Brian Ongioni, Elaine Maynard
-
uMotif is pleased to announce the appointment of renowned expert #eCOA scientist Florence Mowlem, PhD as our Chief Scientific Officer. Working at the intersection of science and technology, Flo has earned a global reputation for innovation in digitizing the capture of #COAs. Flo’s expertise embeds the scientific voice in all functional areas to inform rigorous practices that help sponsors meet the scientific and regulatory requirements of research programs. Read the announcement here: https://lnkd.in/eCBUqiRZ #moversandshakers
-
We are excited to announce that uMotif has purchased ClinOne following a productive two-year #strategicpartnership. Integrating ClinOne’s robust platform of site applications, including #eConsent, with the industry’s most modern #eCOA/#ePRO platform will provide #clinicaltrial sponsors and #CROs with a single, best-in-class solution built on a deep understanding of both the site and patient journey. https://lnkd.in/gF3RWTCB Steve Rosenberg Andrea Valente
-
Outsourcing-Pharma's Liza Laws recently interviewed uMotif Chief Marketing Officer #CMO Elaine Maynard for a new Women in Science profile. Elaine shares insights into her career trajectory and how her life-long interest in the power of clinical trials inspired her 2-decade journey in the #lifesciences industry and commitment to placing #patientsfirst—a philosophy that’s central to her role at uMotif. https://lnkd.in/e3cC_Rh8 #womeninscience #clinicaltrials
-
Today is Glioblastoma Awareness Day. uMotif is forever grateful for the opportunity to work with Jessica Morris, founder of OurBrainBank for Glioblastoma. Jessica let us into her healthcare journey and helped push us to develop truly patient-centric software. https://lnkd.in/d5p6BNRg #GBMDay #OurBrainBank #GBM #Glioblastoma
-
The uMotif team continues to grow. We’re excited to welcome Michael McGloughlin, our new Senior Director, Business Development for EMEA. Michael has more than two decades of experience in pharmaceutical and clinical trial technology business development with industry-leading organizations. We look forward to Michael’s contributions as we continue to bring our modern, patient-centric eCOA/ePRO platform to sponsors and CROs.